716 related articles for article (PubMed ID: 30586694)
1. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
[TBL] [Abstract][Full Text] [Related]
2. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459
[TBL] [Abstract][Full Text] [Related]
3. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.
Sitbon O; Bosch J; Cottreel E; Csonka D; de Groote P; Hoeper MM; Kim NH; Martin N; Savale L; Krowka M
Lancet Respir Med; 2019 Jul; 7(7):594-604. PubMed ID: 31178422
[TBL] [Abstract][Full Text] [Related]
4. Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series.
Mathijssen H; Huitema MP; Bakker ALM; Mager JJ; Snijder RJ; Grutters JC; Post MC
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(1):74-78. PubMed ID: 33093771
[TBL] [Abstract][Full Text] [Related]
5. Riociguat for the treatment of pulmonary arterial hypertension.
Ghofrani HA; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh AM; Langleben D; Kilama MO; Fritsch A; Neuser D; Rubin LJ;
N Engl J Med; 2013 Jul; 369(4):330-40. PubMed ID: 23883378
[TBL] [Abstract][Full Text] [Related]
6. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.
Galiè N; Jansa P; Pulido T; Channick RN; Delcroix M; Ghofrani HA; Le Brun FO; Mehta S; Perchenet L; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Torbicki A
Eur Heart J; 2017 Apr; 38(15):1147-1155. PubMed ID: 28329315
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension.
Tahara N; Dobashi H; Fukuda K; Funauchi M; Hatano M; Ikeda S; Joho S; Kihara Y; Kimura T; Kondo T; Matsushita M; Minamino T; Nakanishi N; Ozaki Y; Saji T; Sakai S; Tanabe N; Watanabe H; Yamada H; Yoshioka K; Sasayama S
Circ J; 2016 May; 80(6):1478-83. PubMed ID: 27180890
[TBL] [Abstract][Full Text] [Related]
8. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
[TBL] [Abstract][Full Text] [Related]
9. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
Li Q; Kuang HY; Wu YH; Lu TW; Yi QJ
Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477
[TBL] [Abstract][Full Text] [Related]
10. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
[TBL] [Abstract][Full Text] [Related]
11. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
[TBL] [Abstract][Full Text] [Related]
12. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients.
Tahara N; Dobashi H; Fukuda K; Funauchi M; Hatano M; Ikeda S; Joho S; Kihara Y; Kondo T; Matsushita M; Minamino T; Nakanishi N; Okano Y; Ozaki Y; Saji T; Sakai S; Tanabe N; Watanabe H; Yamada H; Yoshioka K; Hatta M; Sasayama S
Curr Med Res Opin; 2020 Jun; 36(6):921-928. PubMed ID: 32298185
[No Abstract] [Full Text] [Related]
14. Macitentan in pulmonary hypertension due to left ventricular dysfunction.
Vachiéry JL; Delcroix M; Al-Hiti H; Efficace M; Hutyra M; Lack G; Papadakis K; Rubin LJ
Eur Respir J; 2018 Feb; 51(2):. PubMed ID: 29437943
[TBL] [Abstract][Full Text] [Related]
15. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
Martynyuk TV; Aleevskaya AM
Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938
[TBL] [Abstract][Full Text] [Related]
16. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
[TBL] [Abstract][Full Text] [Related]
17. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
Ghofrani HA; Simonneau G; D'Armini AM; Fedullo P; Howard LS; Jaïs X; Jenkins DP; Jing ZC; Madani MM; Martin N; Mayer E; Papadakis K; Richard D; Kim NH;
Lancet Respir Med; 2017 Oct; 5(10):785-794. PubMed ID: 28919201
[TBL] [Abstract][Full Text] [Related]
18. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.
Hoeper MM; Simonneau G; Corris PA; Ghofrani HA; Klinger JR; Langleben D; Naeije R; Jansa P; Rosenkranz S; Scelsi L; Grünig E; Vizza CD; Chang M; Colorado P; Meier C; Busse D; Benza RL
Eur Respir J; 2017 Sep; 50(3):. PubMed ID: 28889107
[TBL] [Abstract][Full Text] [Related]
19. Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Pulido T; Adzerikho I; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Jing ZC; Le Brun FO; Mehta S; Mittelholzer CM; Perchenet L; Sastry BK; Sitbon O; Souza R; Torbicki A; Zeng X; Rubin LJ; Simonneau G;
N Engl J Med; 2013 Aug; 369(9):809-18. PubMed ID: 23984728
[TBL] [Abstract][Full Text] [Related]
20. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Chin KM; Sitbon O; Doelberg M; Feldman J; Gibbs JSR; Grünig E; Hoeper MM; Martin N; Mathai SC; McLaughlin VV; Perchenet L; Poch D; Saggar R; Simonneau G; Galiè N
J Am Coll Cardiol; 2021 Oct; 78(14):1393-1403. PubMed ID: 34593120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
